Company Performance: Intuitive Surgical, Inc. (NASDAQ: ISRG) reported second-quarter earnings of $2.44 billion, exceeding projections by 4% and showing a 21% growth year-over-year.
Product Launch: The da Vinci 5 surgical system is entering its global launch phase, with Bernstein SocGen Group maintaining an Outperform rating and raising the price target from $675 to $685.
Market Activity: During the quarter, placements of da Vinci systems increased to 180 units, while procedures grew globally by 17%, slightly surpassing consensus estimates.
Investment Perspective: Despite ISRG's growth potential, some analysts believe that certain AI stocks may offer better returns and lower risk compared to Intuitive Surgical.
ISRG
$554.58+Infinity%1D
Analyst Views on ISRG
Wall Street analysts forecast ISRG stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ISRG is 612.47 USD with a low forecast of 440.00 USD and a high forecast of 700.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
20 Analyst Rating
Wall Street analysts forecast ISRG stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ISRG is 612.47 USD with a low forecast of 440.00 USD and a high forecast of 700.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
16 Buy
3 Hold
1 Sell
Strong Buy
Current: 559.520
Low
440.00
Averages
612.47
High
700.00
Current: 559.520
Low
440.00
Averages
612.47
High
700.00
Citi
Buy
to
Neutral
downgrade
$650 -> $635
2025-12-11
Reason
Citi
Price Target
$650 -> $635
2025-12-11
downgrade
Buy
to
Neutral
Reason
Citi downgraded Intuitive Surgical to Neutral from Buy with a price target of $635, down from $650. The firm adjusted ratings and targets in the medical technology sector as part of its 2026 outlook. The group is "bouncing off its lows," and there is further upside potential in 2026, the analyst tells investors in a research note. Citi believes the S&P Equipment and Supplies index "remains undervalued and underappreciated." The firm expects a rebound next year due to company catalysts and sector rotation.
Freedom Capital
Ilya Zubkov
Hold
maintain
$475 -> $560
2025-10-28
Reason
Freedom Capital
Ilya Zubkov
Price Target
$475 -> $560
2025-10-28
maintain
Hold
Reason
Freedom Capital analyst Ilya Zubkov raised the firm's price target on Intuitive Surgical to $560 from $475 and keeps a Hold rating on the shares after "better-than-expected" Q3 earnings. Freedom Capital told investors that despite margin pressure from tariffs and mix, operating leverage and robust demand propelled profitability ahead of expectations, prompting a sharp post-print re-rating despite year-to-date underperformance versus the sector and the broader market. The firm said it maintained a Hold rating as positive expectations may already be reflected in the current valuation.
UBS
Neutral
maintain
$585 -> $600
2025-10-23
Reason
UBS
Price Target
$585 -> $600
2025-10-23
maintain
Neutral
Reason
UBS raised the firm's price target on Intuitive Surgical to $600 from $585 and keeps a Neutral rating on the shares. Strong procedure volume growth and system placements are likely to help sustain the stock's momentum, the analyst tells investors in a post-earnings note.
RBC Capital
Outperform
maintain
$615 -> $625
2025-10-22
Reason
RBC Capital
Price Target
$615 -> $625
2025-10-22
maintain
Outperform
Reason
RBC Capital raised the firm's price target on Intuitive Surgical to $625 from $615 and keeps an Outperform rating on the shares. The company delivered a solid earnings beat, delivering upside surprise of 4% and 20% on sales and EPS, respectively, the analyst tells investors in a research note. The stock also rose thanks to the positive total/dv5 placements, procedure volume raise, and a notable 20% EPS beat as the report helped dispel investor concerns coming into the quarter on dV5 adoption/ramp, hospital environment, and re-manufacturers, RBC adds, noting that it is overall bullish on Intuitive's prospects as Q3 marks the beginning of the trade-in and multi-year replacement cycle for the company.
About ISRG
Intuitive Surgical, Inc. develops, manufactures, and markets da Vinci surgical systems and the Ion endoluminal system. The Company specializes in invasive care and robotic-assisted surgery. Its technologies include the da Vinci surgical systems and the Ion endoluminal system. The da Vinci surgical system is designed to enable surgeons to perform a range of surgical procedures within its targeted general surgery, urologic, gynecologic, cardiothoracic, and head and neck specialties and consists of a surgeon's console or consoles, a patient-side cart, and a high-performance vision system. The Ion endoluminal system is a flexible, robotic-assisted, catheter-based platform for which the cleared indication is minimally invasive biopsies in the lung and consists of a system cart, a controller, a catheter, and a vision probe. Its Ion system extends its commercial offering beyond surgery into diagnostic and endoluminal procedures.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
